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Abstract
Objective: The aim of this study was to generate novel models of bioartificial human 
oral mucosa with increased vascularization potential for future use as an advanced 
therapies medicinal product, by using different vascular and mesenchymal stem cell 
sources.
Background: Oral mucosa substitutes could contribute to the clinical treatment of 
complex diseases affecting the oral cavity. Although several models of artificial oral 
mucosa have been described, biointegration is a major issue that could be favored 
by the generation of novel substitutes with increased vascularization potential once 
grafted in vivo.
Methods: Three types of mesenchymal stem cells (MSCs) were obtained from adipose 
tissue, bone marrow, and dental pulp, and their in vitro potential was evaluated by 
inducing differentiation to the endothelial lineage using conditioning media. Then, 3D 
models of human artificial oral mucosa were generated using biocompatible fibrin- 
agarose biomaterials combined with human oral mucosa fibroblasts and each type 
of MSC before and after induction to the endothelial lineage, using human umbilical 
vein endothelial cells (HUVEC) as controls. The vascularization potential of each oral 
mucosa substitute was assessed in vitro and in vivo in nude mice.
Results: In vitro induction of MSCs kept in culture was able to increase the expres-
sion of VEGF, CD31, and vWF endothelial markers, especially in bone marrow and 
dental pulp- MSCs, and numerous proteins with a role in vasculogenesis become over-
expressed. Then, in vivo grafting resulted in a significant increase in blood vessels 
formation at the interface area between the graft and the host tissues, with signifi-
cantly positive expression of VEGF, CD31, vWF, and CD34 as compared to negative 
controls, especially when pre- differentiated MSCs derived from bone marrow and 
dental pulp were used. In addition, a significantly higher number of cells committed 
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1  |  INTRODUC TION
Oral disorders are very prevalent conditions affecting more than 
3 billion people worldwide, with oral cancer, trauma, and severe 
periodontal disease representing the most prevalent and severe 
cases.1 In most of these cases, treatment is highly dependent on 
the availability of healthy human oral mucosa for replacement 
therapy. In this regard, several models of three- dimensional tissue- 
engineered human oral mucosa have been developed, optimized, 
and characterized using different cells, biomaterials, and signaling 
molecules.2,3 Major applications of bioartificial oral mucosa include 
clinical transplantation in maxillofacial surgery, periodontics, and 
other related therapies.4 Although previously described models 
showed potential usefulness, one of the main clinical limitations of 
bioartificial tissues is the lack of vascularization, which could lead 
to tissue hypoxia once grafted in vivo, which could hinder biointe-
gration.5 In this context, recent studies demonstrated the impor-
tance of generating bioartificial tissues containing a prevascular 
network capable of promoting an efficient supply of nutrients and 
oxygen after implantation.6
Different strategies have been developed to promote blood ves-
sels formation in bioengineered tissues, including the incorporation 
of endothelial cells7, enriching biomaterials with endothelial growth 
factors8 or the direct injection of endothelial cells at the implanta-
tion site7, although none of these strategies demonstrated to be fully 
effective. Due to their demonstrated pro- vasculogenic properties5, 
mesenchymal stem cells (MSCs) have been proposed as a promising 
strategy for vascularization of artificial tissues.9 Interestingly, MSCs 
have been previously used in tissue engineering due to their immuno-
suppressive and anti- apoptotic properties able to favor regeneration 
of damaged tissues10 and their capability to act as potent regulators 
of the immune response.11 In addition, it has been shown that MSCs 
are able to express several angiogenic factors such as VEGF, which 
could facilitate a rapid vascularization of the tissue after implanta-
tion.12,13 Furthermore, it is well known that different types of MSCs 
of the human body are highly heterogeneous.14 For this reason, spe-
cific studies capable of determining the in vitro and in vivo vasculariza-
tion potential of different MSCs sources used in bioengineered oral 
mucosa are in need. In addition, the pro- vasculogenic role of human 
MSCs has not been previously demonstrated in maxillofacial and peri-
odontal scenarios in which the use of MSCs for the generation of a 
human oral mucosa substitutes with improved vascularization poten-
tial could be an interesting approach.
In this work, we have developed novel models of human artifi-
cial oral mucosa based on fibrin- agarose biomaterials combined with 
MSCs able to differentiate to the endothelial cell lineage, in order to 
assess the possibility of inducing rapid vascularization and biointe-
gration after in vivo implantation.
2  |  MATERIAL S AND METHODS
2.1  |  Primary cell cultures
2.1.1  |  Human oral mucosa fibroblasts (HFOM)
To generate primary cell cultures of human oral mucosa fibroblasts 
(HFOM), small biopsies of human oral mucosa were obtained from 
healthy donors subjected to minor oral surgery with local anes-
thesia. In brief, human oral mucosa (HOM) fibroblasts were ob-
tained by enzymatic digestion of the HOM stroma using 2 mg/
ml solution of Clostridium histolyticum type I collagenase (Gibco 
BRL) at 37ºC for 6 hours with agitation. Isolated HOM fibroblasts 
were cultured in Dulbecco's Modified Eagle's Medium (DMEM) 
(Sigma- Aldrich/Merck) supplemented with 10% fetal bovine 
serum (Sigma- Aldrich/Merck) and 1% antibiotics and antimycotics 
(100 U/ml penicillin G, 100 mg/ml streptomycin, and 0.25 mg/ml 
amphotericin B) (Sigma- Aldrich/Merck) using 75 cm2 culture flasks 
with filter caps (Sarstedt, Nümbrecht, Germany), as previously de-
scribed by the research group.15,16
2.1.2  |  Mesenchymal stem cells (MSCs)
To generate primary cultures of three types of human MSCs, we 
obtained small biopsies from adipose tissue, bone marrow, and 
dental pulp following previously described protocols.17,18,19,16 All 
tissue types were washed in phosphate- buffered saline (PBS) con-
taining antibiotics and antimycotics and enzymatically digested 
for 6 h at 37ºC using a 2 mg/ml solution of Clostridium histolyticum 
type I collagenase (Gibco BRL). Isolated MSCs from adipose tis-
sue (ADSC), bone marrow (BMSC), and dental pulp (DPSC) were 
cultured in 75 cm2 culture flasks with filter caps (Sarstedt) using 
DMEM supplemented with 10% fetal bovine serum and 1% anti-
biotics/antimycotics. In all cases, cells were cultured at 37ºC in 
a humidified incubator with 5% CO2 using standard cell culture 
to the endothelial lineage expressing the same endothelial markers were found within 
the bioartificial tissue.
Conclusion: Our results suggest that the use of pre- differentiated MSCs could con-
tribute to a rapid generation of a vascular network that may favor in vivo biointegra-
tion of bioengineered human oral mucosa substitutes.
K E Y W O R D S
mesenchymal stem cells, oral mucosa, tissue engineering, vascularization
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conditions. The culture medium was changed every 2– 3 days. 
Once the cells reached 70% confluence, cells were dissociated 
with 0.25% trypsin- ethylenediaminetetraacetic acid (EDTA) 
(Sigma- Aldrich/Merck).
2.1.3  |  Human umbilical vein endothelial cells (HUVEC)
Human umbilical vein endothelial cells (HUVEC) were commercially 
obtained from the American Type Culture Collection (ATCC). HUVEC 
were cultured in Endothelial Growth Medium (Sigma- Aldrich/Merck) 
using 75 cm2 culture flasks with filter caps (Sarstedt). Cells were cul-
tured at 37ºC in a humidified incubator with 5% CO2, and the culture 
medium was changed every 2– 3 days.
2.2  |  MSCs characterization
Multilineage differentiation potential of isolated MSCs was confirmed 
by subculturing MSCs on chamber slides and inducing differentia-
tion to adipogenic, chondrogenic, and osteogenic cell lineages using 
specific conditioning media. Histochemical analysis was performed 
by oil red O, alizarin red S, and alcian blue as previously described.20 
In addition, ADSC, BMSC, and DPSC were characterized to confirm 
their stemness profile before endothelial induction. For this, expres-
sion of typical MSCs markers was evaluated by flow cytometry using 
a Human MSC Analysis BD Stemflow™ kit (BD Biosciences). In brief, 
5 × 105 cells corresponding to ADSC, BMSC, and DPSC were placed 
in flow cytometry tubes and washed with 2 ml of staining buffer (R&D 
Systems Inc). Then, Fc receptors were blocked by incubating the cells 
for 5 min with 2 ml of PBS containing 0.1% bovine serum albumin 
and 0.1% FBS. Next, cells were stained with a positive cocktail (FITC 
CD90, PerCP- Cy CD105, and APC CD73) and a negative MSC cock-
tail (PE CD45, PE CD34, PE CD11b, PE CD19, and PE HLA- DR) and 
incubated for 45 min at 4ºC in darkness. Once cells were labeled, cells 
were placed in a staining buffer and analyzed using a FACSCalibur flow 
cytometer (BD Biosciences).
2.3  |  Endothelial differentiation of MSCs
To induce the endothelial differentiation of non- differentiated 
ADSC, BMSC, and DPSC (called ndADSC, ndBMSC, and ndDPSC, 
respectively), these cells were cultured for 21 days in an endothelial 
differentiation medium composed by 199 medium (Sigma- Aldrich/
Merck) supplemented with 20% FBS, 1.5% endothelial growth sup-
plement from bovine neural tissue, and 1.5% antibiotics and antimy-
cotics (100 U/ml penicillin G, 100 mg/ml streptomycin, and 0.25 mg/
ml amphotericin B) as previously reported.21 The culture medium 
was changed three times a week, and subconfluent cells were disso-
ciated using 0.25% EDTA (all reagents, from Sigma- Aldrich/Merck). 
Cells induced with endothelial differentiation medium for 21 days 
were called differentiated cells (dADSC, dBMSC, and dDPSC, 
respectively).
2.4  |  In vitro immunofluorescence analysis
To identify the expression of relevant endothelial differentiation 
markers in ADSC, BMSC, and DPSC, we carried out immunofluo-
rescence analyses using specific antibodies anti- vascular endothelial 
growth factor (VEGF), anti- CD31 (PECAM- 1), anti- von Willebrand 
Factor (vWF), and anti- CD34. These analyses were carried out on 
native, non- differentiated, and differentiated MSCs. HUVEC was 
used as a control group. First, 104 cells were cultured in chamber 
slides (NuncTM Lab- TekTM Thermo Fisher Scientific), fixed with 70% 
ethanol, washed in PBS, and blocked for 30 min with normal horse 
serum and casein (Vector Laboratories). Then, samples were incu-
bated for 1 h with primary antibodies with a dilution 1:100 for anti- 
VEGF (Abcam), 1:500 for anti- CD31 (PECAM- 1; Abcam), 1:100 for 
anti- vWF (Abcam), and 1:2500 for anti- CD34 (Abcam), washed in 
PBS, and incubated with secondary antibodies for 1 h at room tem-
perature using FITC- conjugated anti- mouse (Sigma- Aldrich/Merck) 
or CY3- conjugated anti- rabbit antibodies (Sigma- Aldrich/Merck). 
All study samples and controls were counterstained with DAPI 
(Vector Laboratories) and analyzed using an Eclipse 90i microscope 
(Nikon). Results were evaluated by three independent histologists 
using a semiquantitative method scoring the signal as strongly posi-
tive (+++), positive (++), mildly positive (+), slightly positive (+/−), or 
negative (−).
2.5  |  Expression analysis of vascularization- 
related proteins
Expression of relevant proteins playing a role in promoting vascu-
larization was assessed in primary cell cultures of non- differentiated 
and differentiated ADSC, BMSC, and DPSC using a human angiogen-
esis array kit (R&D Systems Inc.). First, 106 cells of each type were 
harvested and mixed with 1.0 ml of MCL1 mammalian cell lysis ex-
traction buffer (Sigma- Aldrich/Merck) containing 20% of Tris- EDTA, 
NaCl, SDS (lauryl sulfate), DOC (deoxycholic acid), Igepal CA, and 
1% of protease inhibitor cocktail. Cell lysates were then centrifuged 
at 10,000 g for 10 min at 4ºC, and the supernatant was collected. 
Protein concentration was measured using a Pierce BCA- 200 Assay 
Kit (Thermo Fisher Scientific). Then, the protein array membranes 
were blocked with 2.0 ml of the buffer included in the kit, and 1.0 ml 
of protein extract corresponding to each type of sample was added 
to the membrane at final concentration of 300 µg/ml. After this, all 
samples were treated with 15 µl of reconstituted detection antibody 
cocktail, washed, and incubated with 2.0 ml of Streptavidin- HRP. 
Finally, samples were washed and Chemi Reagent Mix was spread all 
over the membranes and incubated for one minute at room tempera-
ture prior to X- ray film exposition for 10 min. Films were scanned, 
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and signal intensity was quantified at each spot using Image J soft-
ware (Wayne Rasband, NIH). Analyses were carried out using trip-
licates (n = 3).
2.6  |  Generation of novel models of human oral 
mucosa stroma with pro- vascularization potential
To determine the vascularization potential of each cell type in a 
three- dimensional tissue substitute generated by tissue engineer-
ing, we generated novel models of human oral mucosa stroma 
(HOM) based on the previously described fibrin- agarose biomate-
rial. In brief, hydrogels were developed with a mixture of human 
plasma combined with type VII agarose and cultured cells, as 
previously described.22,15 To prevent gel fibrinolysis, the mixture 
was supplemented with tranexamic acid Amchafibrin™ (Fides 
Ecopharma), and 1% calcium chloride was added at the final step 
to induce polymerization. This mixture was aliquoted on 6- well 
plates with 24 mm Transwell Permeable Supports (Corning Life 
Sciences). Four different models were generated: 1) artificial oral 
mucosa stroma containing 5 × 105 oral mucosa fibroblasts (HOM- 
HFOM). This is the previously developed bioartificial tissue and 
was used as negative control, 2) artificial oral mucosa stroma con-
taining 2.5 × 105 oral mucosa fibroblasts and 2.5 × 105 HUVEC 
(HOM- HUVEC). This tissue substitute was used as positive con-
trol; 3) artificial oral mucosa stroma containing 2.5 × 105 oral 
mucosa fibroblasts and 2.5 × 105 non- differentiated MSCs (HOM- 
ndADSC, HOM- ndBMSC, or HOM- ndDPSC); and 4) artificial oral 
mucosa stroma containing 2.5 × 105 fibroblasts and 2.5 × 105 dif-
ferentiated MSCs (HOM- dADSC, HOM- dBMSC, or HOM- dDPSC) 
(Figure 1).
2.7  |  In vivo evaluation of bioengineered 
human oral mucosa models
To determine the in vivo vascularization potential of each model of 
bioengineered oral mucosa stroma, HOM models were grafted on 
immune- deficient Foxn1nu−/Foxn1nu− athymic mice. Shortly, mice 
were anesthetized using a mixture of 0.001 mg/g of body weight 
of acepromazine— Calmo- Neosan™— (Boehringer Ingelheim,) and 
0.15 mg/g of body weight of ketamine— Imalgene 1000— (Merial 
labs). Then, a skin area of 24 mm2 was surgically removed from the 
interscapular area of each animal and the bioengineered oral mu-
cosa stroma models were trimmed to the same diameter. Samples 
were grafted at the injury site using absorbable suture material, and 
a plastic ring was implanted and sutured at the injury borders to pre-
vent border contraction. All mice were euthanized one week after 
implantation of the bioengineered tissue for histological and immu-
nohistochemical analyses.
2.8  |  Histology and immunohistochemistry
Tissues were fixed in 4% formaldehyde and embedded in paraffin 
in order to obtain 5 μm- thick histological sections. Tissue sections 
were dewaxed, rehydrated, and stained with hematoxylin and eosin 
(HE) for histological analysis.
First, the localization and distribution of the human cells grafted 
in the animals were determined by immunohistochemistry for the 
anti- human mitochondria- specific antigen using anti- Mitochondria 
clone 113– 1 antibodies (Sigma- Aldrich/Merck), using a 1:80 dilution 
of the primary antibody. Then, to evaluate the in vivo vascularization 
potential of each HOM model, an immunohistochemical analysis was 
performed using the well- established markers of endothelial cells 
and blood vessels23,24 anti- VEGF (Abcam) with 1:100 dilution, an-
ti- CD31 (PECAM- 1, Abcam) with 1:500 dilution, anti- vWF (Abcam) 
with 1:100 dilution, and anti- CD34 with 1:2500 dilution as were pre-
viously used for in vitro analysis. In all cases, tissue sections were de-
paraffinized using xylene and rehydrated through a graded series of 
alcohols (100%, 96%, 70%, 50%, and water) before antigen retrieval 
with 0.01 M citrate buffer, pH 6.0, and 0.01 M EDTA buffer, pH 8.0, at 
95ºC. Then, samples were prehybridized for 30 min with normal horse 
serum and casein (Vector Laboratories). Then, samples were incu-
bated overnight with primary antibodies at 4ºC, washed with PBS, and 
incubated with secondary antibodies for 1 h at room temperature. The 
complex epitope- antibody was detected using 3,3- diaminobenzidine 
- DAB- (Vector Laboratories), and tissue sections were counterstained 
for 20 s using Harry's hematoxylin. In all cases, images were obtained 
using a Pannoramic® DESK II DW scanner (3D Histotech).
F I G U R E  1  Schematic representation of the experimental groups used in the present work. (A) In vitro control group of human umbilical 
vein endothelial cells (HUVEC) kept in culture. (B) In vitro non- differentiated MSCs (ndMSCs), including adipose stem cells (ndADSC), bone 
marrow stem cells (ndBMSC), and dental pulp stem cells (ndDPSC) kept in culture. (C) In vitro differentiated MSCs (dMSCs), including 
adipose stem cells (dADSC), bone marrow stem cells (dBMSC), and dental pulp stem cells (dDPSC) kept in culture. (D) Generation of negative 
control bioartificial human oral mucosa substitutes (HOM- HFOM) containing oral mucosa fibroblasts (hOM Fibroblasts). (E) Generation of 
positive control bioartificial human oral mucosa substitutes (HOM- HUVEC) containing human umbilical vein endothelial cells (HUVEC) and 
hOM Fibroblasts. (F) Generation of bioartificial human oral mucosa substitutes (HOM- ndMSCs) containing non- differentiated MSCs and 
hOM Fibroblasts. (G) Generation of bioartificial human oral mucosa substitutes (HOM- dMSCs) containing differentiated MSCs and hOM 
Fibroblasts. (H) Immunohistochemical analysis of anti- human Mitochondria in bioartificial human oral mucosa substitutes implanted on 
athymic mice. Peripheric areas of the injury site corresponding to mouse host tissue are squared in green. Human oral mucosa substitutes 
implanted on the athymic mice are squared in orange. Higher magnification images showing human origin cells (in brown) and host mouse 
cells (in blue), along with blood vessels showing positive signal (white arrows) and negative signal (black arrows) are shown in panels to the 
right. Scale bars: 100 µm
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For each vascular marker, microvessel density (MVD) was mea-
sured by quantifying the number of blood vessels per mm2 of tis-
sue surface at the vascular interphase area of each sample type. In 
addition, the number of cells showing positive signal was also quanti-
fied at the cellular area of the grafted tissues to determine the pres-
ence of cells committed to the endothelial lineage.
6  |    BLANCO- ELICES Et AL.
2.9  |  Statistical analysis
To analyze the protein expression results obtained with the human 
angiogenesis array kit, we first determined the average expres-
sion found for each type of sample and calculated the fold- change 
value of differentiated cells vs. non- differentiated cells of the same 
cell type (for instance, dADSC vs. ndADSC). Then, a rank test was 
applied to compare the results obtained for differentiated cells 
vs. non- differentiated cells of the same cell type (for instance, 
dADSC vs. ndADSC). Proteins showing 1) an increase of at least 
20% expression upon differentiation (fold- change >1.20) and 2) a 
p value below 0.05 for the rank test were selected as statistically 
significant.
For the analysis of vascular markers, quantification results of blood 
vessels or cells showing positive signal for each marker were com-
pared with negative control HOM- HFOM and positive control HOM- 
HUVEC using the Pairwise Mann- Whitney exact test, since samples 
did not fulfill normality criteria. p values below.05 were considered 
statistically significant, and tests were performed double- tailed. These 
comparisons were carried out using the Real Statistics Resource Pack 
software (Release 7.2) available at www.real- stati stics.com.
2.10  |  Research committee approval and 
ethics statement
This study and the donation of the tissues used in this work (oral 
mucosa and tissues rich in MSC) were approved by the Research 
and Ethics Committee in Biomedical Research of Granada (Comité 
Coordinador de Ética de la Investigación Biomédica, ref. 0116- N- 19, 
approval date 29/05/2019). All tissue donors provided informed 
consent. Animal experimentation was approved by the Animal 
Experimentation Ethics Committee of Granada (Comité de Ética 
y Experimentación Animal, CEEA) and Consejería de Agricultura, 
Ganadería, Pesca y Desarrollo Sostenible, Junta de Andalucía, 
Spain, protocol code 08/07/2019/123, date of approval January, 
10/09/2019.
3  |  RESULTS
3.1  |  Phenotype characterization of human MSCs
Histological evaluation of MSCs cultures (ADSC, BMSC, and DPSC) 
demonstrated that these cells were able to adhere to the culture 
flask surface, and the typical mesenchymal spindle- shape, elongated 
morphology. Specific conditioning media revealed that MSCs used in 
this study were able to differentiate into adipogenic, chondrogenic, 
and osteogenic cell lineages, as determined by alizarin red S, alcian 
blue, and oil red O staining (Figure 2). Flow cytometry characteriza-
tion of native MSCs cultures demonstrated that ndADSC, ndBMSC, 
and ndDPSC were positive for CD73, CD90, and CD105 markers. 
The analysis of CD73 marker showed 99.7% positive cells in ADSC, 
95.4% in BMSC, and 99.3% in DPSC, whereas CD90 was positive in 
85.2% of ndADSC, 87.0% of ndBMSC, and 97.8% of ndDPSCS, and 
CD105 was positive in 84.8% ndADSC, 89.7% ndBMSC, and 97.3% 
ndDPSC. Negative cocktail markers (CD45, CD34, CD14 or CD11b, 
CD79a or CD19, and HLA- DR) were absent in all mesenchymal stem 
cell types (Figure 2).
3.2  |  In vitro differentiation of human MSCs
3.2.1  |  Immunofluorescence assay
Semiquantitative analysis of several markers of endothelial differen-
tiation revealed that HUVEC expressed VEGF, CD31, and vWF, but 
were negative for CD34. In the case of non- differentiated MSCs, 
most markers were negative, except for ndBMSC, which had mildly 
positive expression of VEGF and vWF. Moreover, ndDPSC revealed 
slightly positive vWF expression. When MSCs were induced in vitro, 
we found an increase in the expression of VEGF, CD31, and vWF. 
For VEGF, we found a mildly positive signal in dADSC and a positive 
signal in dBMSC and dDPSC, whereas CD31 was slightly positive 
in dBMSC, and dDPSC and vWF showed strongly positive signal in 
dADSC and positive signal in dBMSC and dDPSC, and CD34 was 
negative in all cell types (Figure 3; Table 1).
3.2.2  |  Protein expression analysis
Several proteins became upregulated in cells subjected to in vitro 
induction. As shown in Figure 4, 11 out of the 55 proteins ana-
lyzed (20%) were upregulated in dDPSC, including Amphiregulin, 
Artemin, EG- VEGF, Endoglin, FGF basic, HGF, IGFBP- 2, IGFBP- 3, 
LAP (TGF- β1), Platelet Factor 4 (PF4), and VEGF, with three of these 
proteins (Amphiregulin, PF4, and VEGF) showing more than 100- 
fold expression upon differentiation. Eight proteins (14.5%) were 
significantly upregulated in dBMSC, including CXCL16, Coagulation 
Factor III, EGF, FGF- 4, LAP (TGF- β1), Serpin F1, TIMP- 1, and TIMP- 
4. Interestingly, 6 of the 8 proteins upregulated in dBMSC were also 
found to be overexpressed in differentiated dADSC, which showed 
10 proteins (18.2%) upregulated upon induction, including CXCL16, 
EGF, FGF- 4, IL- 1β, PF4, Serpin F1, Thrombospondin- 2, TIMP- 1, 
TIMP- 4, and Vasohibin.
3.3  |  In vivo evaluation of the vascularization 
potential of the novel models of HOM
3.3.1  |  Histological and immunohistochemical analysis
All artificial HOM models grafted in vivo were properly biointegrated 
in the host animal, and we did not find any microscopical signs of 
hemorrhage, tumorigenesis, rejection, infection, or other side ef-
fects linked to the grafted tissues.
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F I G U R E  2  Phenotype characterization of human MSCs. (A) Multilineage differentiation capabilities of ADSC, BMSC, DPSC after 
adipogenic, chondrogenic, and osteogenic induction Scale bars: 100 µm. (B) Evaluation of the stemness profile of MSCs by the detection of 
CD73, CD90, and CD105 markers by flow cytometry
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As shown in Figure 5, histological analysis of grafted HOM re-
vealed the presence of three histological zones at the grafting site 
(zones A, B, and C). Zone A corresponded to the remaining artifi-
cial oral mucosa stroma substitute implanted in the animals. Zone B 
corresponded to the rest of the grafted HOM containing abundant 
cells of the bioartificial tissue. Finally, zone C represented the in-
terface area between the native tissues belonging to the host ani-
mals and the grafted HOM, and contained numerous blood vessels. 
Interestingly, cells tended to concentrate at specific zones, espe-
cially at zone B, followed by zone C, while very few cells were found 
in zone A.
In order to confirm the human origin of HFOM, HUVEC, and 
MSCs implanted in mice, samples were analyzed using anti- human 
mitochondria antigen antibodies. Results revealed a positive 
expression in the grafted tissue, whereas peripheral host tissues 
showed negative signal (Figure 1 and supplementary Figure S1).
3.3.2  |  Analysis of vascular markers by 
Immunohistochemistry
To determine the vascularization potential of the novel models of 
HOM, we analyzed the presence of structures showing positive 
signal for each specific marker in each tissue type grafted in vivo 
(Figures 6- 10). In general, zone A was negative for the analyzed 
markers, whereas zone B contained numerous positive cells and 
zone C was rich in vessels showing positive immunohistochemical 
staining and was used to determine MVD. In addition, the use of 
F I G U R E  3  In vitro characterization of human umbilical vein endothelial cells (HUVEC), non- differentiated MSCs (ndMSCs) and 
differentiated MSCs (dMSCs) using CD34, VEGF, CD31 and vWF immunofluorescence. ndADSC: non- differentiated adipose stem cells; 
ndBMSC: non- differentiated bone marrow stem cells; ndDPSC: non- differentiated dental pulp stem cells; dADSC: differentiated adipose 
stem cells; dBMSC: differentiated bone marrow stem cells; dDPSC differentiated dental pulp stem cells. Scale bars: 50 µm
TA B L E  1  Semiquantitative analysis of relevant vascular markers in human umbilical vein endothelial cells (HUVEC), non- differentiated 
MSCs (ndMSCs), and MSCs differentiated in vitro (dMSCs). Expression was classified as strongly positive (+++), positive (++), mildly positive 
(+), slightly positive (+/−), or negative (−)
HUVEC ndADSC ndBMSC ndDPSC dADSC dBMSC dDPSC
VEGF + − + − + ++ ++
CD31 + − − − − +/− +/−
vWF +++ − + +/− +++ ++ ++
CD34 − − − − − − −
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anti- human mitochondria antigen antibodies allowed us to find that 
some of these blood vessels, approximately half of them, were of 
human origin, whereas other vessels consisted of host mouse cells 
(Figure 1).
First, analysis of MVD in zone C using VEGF markers (Figures 6 
and 10) showed that the number of vessels found in HOM- HUVEC 
positive controls was significantly higher than HOM- HFOM negative 
controls (p = 0.0188). For HOM generated with non- differentiated 
MSCs, only HOM- ndBMSC showed lower MVD than positive con-
trols (p = 0.0106), while HOM- ndDPSC was significantly higher than 
negative controls (p = 0.0244). HOM- ndADSC, HOM- nd- DPSC, and 
all HOM tissues generated with differentiated cells were comparable 
to positive controls (p > 0.05 for all of them). Interestingly, MVD was 
significantly higher in HOM- dBMSC as compared to HOM- ndBMSC 
(p = 0.0188) and in HOM- dDPSC as compared to HOM- ndDPSC 
(p = 0.0244). When VEGF- positive cells were quantified in zone B, we 
found very few positive cells in HOM- HFOM negative controls and in 
HOM- ndDPSC and very high number in HOM- HUVEC positive con-
trols, with differences being statistically significant (p < 0.0001 for 
HOM- HFOM vs. HOM- HUVEC and p = 0.0001 for HOM- ndDPSC 
vs. HOM- HUVEC). HOM generated with non- differentiated MSCs 
showed significant differences with positive controls (p = 0.0019 for 
HOM- ndADSC, p < 0.0001 for HOM- ndBMSC and p = 0.0001 for 
HOM- ndDPSC), and HOM- ndADSC (p = 0.0019) and HOM- ndBMSC 
(p = 0.0142) were also significantly higher than negative controls. 
Finally, HOM containing differentiated MSCs showed statistical dif-
ferences with negative controls (p < 0.0001 for HOM- dADSC and 
HOM- dDPSC and p = 0.0019 for HOM- dBMSC), but were compara-
ble to positive controls (p > 0.05) and were significantly higher than 
HOM containing non- differentiated MSCs (p = 0.0019 for HOM- 
ndADSC vs HOM- dADSC and for HOM- ndBMSC vs HOM- dBMSC, 
and p < 0.0001 for HOM- ndDPSC vs. HOM- dDPSC).
For CD31 (Figures 7 and 10), we found that the MVD in zone C 
was significantly lower in negative controls (p = 0.0002) and HOM 
generated with non- differentiated MSCs (p < 0.0001 for HOM- 
ndADSC, p = 0.0008 for HOM- ndBMSC, and p = 0.0002 for HOM- 
ndDPSC) than in positive controls, with non- significant differences 
among these samples. For HOM containing differentiated MSCs, 
HOM- dADSC (p = 0.0028) and HOM- dDPSC (p = 0.0106) con-
tained significantly lower number of vessels than positive controls, 
although HOM- dBMSC was similar to positive controls (p > 0.05). 
HOM- dBMSC and HOM- dDPSC were significantly higher than 
negative controls (p = 0.0106 and p = 0.0142, respectively). HOM- 
dADSC and HOM- dDPSC showed significantly higher MVD than 
HOM- ndADSC (p = 0.0003) and HOM- ndDPSC (p=0.0188). At zone 
B, the number of CD31- positive cells was significantly higher in posi-
tive controls than in negative controls (p < 0.0001). HOM containing 
non- differentiated MSCs had significantly fewer cells than positive 
controls (p < 0.0001 for all comparisons), although HOM- ndBMSC 
and HOM- ndDPSC were significantly higher than negative controls 
(p < 0.0001). For differentiated HOM, we found a significant in-
crease in positive cells, and HOM- dBMSC and HOM- dDPSC became 
comparable to positive controls (p > 0.05).
Analysis of MVD as determined by vWF immunostaining of ves-
sels found in zone C (Figures 8 and 10) revealed again that the number 
of vWF- positive cells was higher in positive controls as compared to 
negative controls (p < 0.0001). HOM with non- differentiated MSCs 
had lower number of vessels than positive controls (p < 0.0001 for 
F I G U R E  4  Proteins upregulated in dADSC, dBMSC, and dDPSC subjected to in vitro endothelial differentiation using inductive 
endothelial culture media. For each protein, the average fold- change expression of non- differentiated ndMSCs versus differentiated dMSCs 
is shown for each cell type. Error bars correspond to standard deviations. Statistically significant differences of non- differentiated MSCs 
versus differentiated MSCs are highlighted with asterisks (*)
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HOM- ndADSC, p = 0.0142 for HOM- ndBMSC p = 0.0315 for HOM- 
ndDPSC), and HOM- ndBMSC and HOM- ndDPSC were significantly 
higher than negative controls (p = 0.0244 and p = 0.0001, respec-
tively). Upon differentiation, we found a significant increase of MVD 
in HOM- dADSC (p = 0.0005) and HOM- dBMSC (p = 0.0244), and 
HOM- dBMSC and HOM- dDPSC became comparable to positive 
controls (p > 0.05). Regarding the number of vWF- positive cells 
found at zone B, positive controls were significantly higher than neg-
ative controls (p < 0.0001), and HOM with non- differentiated MSCs 
showed significantly fewer vWF- positive cells than positive con-
trols (p < 0.0001 for HOM- ndADSC, p = 0.0004 for HOM- ndBMSC 
p = 0.0048 for HOM- ndDPSC) and significantly more positive cells 
than negative controls (p = 0.0400 for HOM- ndADSC, p = 0.0004 
for HOM- ndBMSC p = 0.0004 for HOM- ndDPSC). For HOM 
containing differentiated cells, we found a significant increase of 
vWF- positive cells in HOM- dDPSC as compared to HOM- ndDPSC 
(p = 0.0004), and HOM- dBMSC and HOM- dDPSC became statisti-
cally similar to positive controls (p > 0.05).
Finally, each type of sample was evaluated using CD34 markers 
(Figures 9 and 10 and Supplementary Figure S1). Results showed 
that MVD at zone C was very high in positive controls and very low 
in negative controls (p = 0.0001 for the comparison of both con-
trols). The number of CD34- positive vessels found in HOM with 
non- differentiated cells was significantly higher than negative 
controls (p < 0.0001 for all types of HOM with non- differentiated 
cells), but significantly lower than positive controls (p = 0.0152 for 
HOM- ndADSC, p = 0.0055 for HOM- ndBMSC p = 0.0206 for HOM- 
ndDPSC). When differentiated cells were used, HOM- dBMSC and 
HOM- dDPSC became similar to positive controls (p > 0.05), but 
HOM- dADSC was lower than positive controls (p = 0.0360). At zone 
B, positive controls had more CD34- positive cells than negative con-
trols (p = 0.0004). When HOM containing non- differentiated cells 
were analyzed, we found very few positive cells in HOM- ndADSC 
(p = 0.0008 vs. positive controls), but the number of CD34- positive 
cells found in HOM- ndBMSC and HOM- ndDPSC was not signifi-
cantly lower than positive controls (p > 0.05). Then, HOM generated 
with differentiated MSCs showed a trend to show a higher number 
of CD34- positive cells than positive control, which reached statisti-
cal significance in the case of HOM- dADSC (p = 0.0238).
4  |  DISCUSSION
Biofabrication methods applied to tissue engineering have been 
significantly improved over the past few years. However, vasculari-
zation is still one of the main limitations of bioengineered tissues. 
F I G U R E  5  Histological analysis of the different bioartificial human oral mucosa models generated in the present work after one week 
of in vivo follow- up using hematoxylin and eosin staining (HE). For each sample, low- magnification images are shown on top, and the three 
zones (A, B, and C) identified in each sample are shown at higher magnification in the lower panels. HOM- HFOM: negative control group 
containing human oral mucosa fibroblasts; HOM- HUVEC: positive control group containing human umbilical vein endothelial cells and 
oral mucosa fibroblasts; HOM- ndMSCs: human oral mucosa substitutes containing non- differentiated MSCs and oral mucosa fibroblasts, 
including non- differentiated adipose stem cells (ndADSC), non- differentiated bone marrow stem cells (ndBMSC) and non- differentiated 
dental pulp stem cells (ndDPSC); HOM- dMSCs: human oral mucosa substitutes containing differentiated MSCs and oral mucosa fibroblasts, 
including differentiated adipose stem cells (dADSC), differentiated bone marrow stem cells (dBMSC), and differentiated dental pulp stem 
cells (dDPSC). Scale bars: 20 µm
    |  11BLANCO- ELICES Et AL.
It is well known that human tumors cannot grow more than 3 mm 
without the formation of novel vessels by angiogenesis.24 In tissue 
engineering, vessel formation is necessary for the grafted tissue to 
receive nutrients and oxygen,25 and vascularization is a crucial step 
for tissue biocompatibility and viability at the receptor niche. In vivo 
formation of blood vessels can be achieved either by vasculogenesis 
or by angiogenesis. Vasculogenesis refers to differentiation of pre-
cursor cells into endothelial cells able to form blood vessels de novo, 
whereas angiogenesis is a process by which preexisting blood ves-
sels spread into tissues by sprouting or intussusception.26
Numerous models of human bioengineered oral mucosa have 
been described, with some of them showing promising clinical results 
F I G U R E  6  Immunohistochemical analysis of VEGF expression in each sample grafted in laboratory animals for one week. HOM- HFOM: 
negative control group containing human oral mucosa fibroblasts; HOM- HUVEC: positive control group containing human umbilical vein 
endothelial cells and oral mucosa fibroblasts; HOM- ndMSCs: human oral mucosa substitutes containing non- differentiated MSCs and oral 
mucosa fibroblasts, including non- differentiated adipose stem cells (ndADSC), non- differentiated bone marrow stem cells (ndBMSC) and 
non- differentiated dental pulp stem cells (ndDPSC); HOM- dMSCs: human oral mucosa substitutes containing differentiated MSCs and oral 
mucosa fibroblasts, including differentiated adipose stem cells (dADSC), differentiated bone marrow stem cells (dBMSC), and differentiated 
dental pulp stem cells (dDPSC). Scale bars: 20 µm
F I G U R E  7  Immunohistochemical analysis of CD31 expression in each sample grafted in laboratory animals for 1 week. HOM- HFOM: 
negative control group containing human oral mucosa fibroblasts; HOM- HUVEC: positive control group containing human umbilical vein 
endothelial cells and oral mucosa fibroblasts; HOM- ndMSCs: human oral mucosa substitutes containing non- differentiated MSCs and oral 
mucosa fibroblasts, including non- differentiated adipose stem cells (ndADSC), non- differentiated bone marrow stem cells (ndBMSC), and 
non- differentiated dental pulp stem cells (ndDPSC); HOM- dMSCs: human oral mucosa substitutes containing differentiated MSCs and oral 
mucosa fibroblasts, including differentiated adipose stem cells (dADSC), differentiated bone marrow stem cells (dBMSC), and differentiated 
dental pulp stem cells (dDPSC). Scale bars: 20 µm
12  |    BLANCO- ELICES Et AL.
in patients.27,28 However, a fully functional oral mucosa model able 
to generate an efficient vascular network once grafted in vivo is in 
need. In this regard, interesting recent reports demonstrated the 
usefulness of cultured human endothelial cells to generate a prevas-
cularized oral mucosa.25 These authors used HUVEC isolated from 
human umbilical cord combined with extracellular matrix nanofilms 
biomaterials and demonstrated that these cells were able to differ-
entiate in situ and form blood capillaries in the oral mucosa stroma. 
Although this method is promising, the use of HUVEC cells is sub-
jected to several limitations such as the low in vitro proliferation ca-
pability of these cells or the high likelihood of immunogenic rejection 
if the cells are used allogenically.29,30
F I G U R E  8  Immunohistochemical analysis of vWF expression in each sample grafted in laboratory animals for one week. HOM- HFOM: 
negative control group containing human oral mucosa fibroblasts; HOM- HUVEC: positive control group containing human umbilical vein 
endothelial cells and oral mucosa fibroblasts; HOM- ndMSCs: human oral mucosa substitutes containing non- differentiated MSCs and oral 
mucosa fibroblasts, including non- differentiated adipose stem cells (ndADSC), non- differentiated bone marrow stem cells (ndBMSC), and 
non- differentiated dental pulp stem cells (ndDPSC); HOM- dMSCs: human oral mucosa substitutes containing differentiated MSCs and oral 
mucosa fibroblasts, including differentiated adipose stem cells (dADSC), differentiated bone marrow stem cells (dBMSC), and differentiated 
dental pulp stem cells (dDPSC). Scale bars: 20 µm
F I G U R E  9  Immunohistochemical analysis of CD34 expression in each sample grafted in laboratory animals for one week. HOM- HFOM: 
negative control group containing human oral mucosa fibroblasts; HOM- HUVEC: positive control group containing human umbilical vein 
endothelial cells and oral mucosa fibroblasts; HOM- ndMSCs: human oral mucosa substitutes containing non- differentiated MSCs and oral 
mucosa fibroblasts, including non- differentiated adipose stem cells (ndADSC), non- differentiated bone marrow stem cells (ndBMSC) and 
non- differentiated dental pulp stem cells (ndDPSC); HOM- dMSCs: human oral mucosa substitutes containing differentiated MSCs and oral 
mucosa fibroblasts, including differentiated adipose stem cells (dADSC), differentiated bone marrow stem cells (dBMSC), and differentiated 
dental pulp stem cells (dDPSC). Scale bars: 20 µm
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A possible alternative to highly differentiated cells such as 
HUVEC is the use of MSCs, due to their low immunogenicity, 
high proliferation rate, and high differentiation potential.16,31 In 
fact, MSCs have been previously used for vascularization strate-
gies.32,33,34,35 However, most of these approaches are focused on 
skin, bone, and spinal cord regeneration, and there is no evidence for 
the use of MSCs for the generation of prevascularized oral mucosa 
substitutes. In this work, we developed novel human artificial oral 
mucosa stroma models using three different MSCs sources to deter-
mine the vascularization potential of each MSC type and assess the 
possibility of inducing rapid vascularization after in vivo implantation.
First, we demonstrated that the three types of MSCs used in this 
work had intrinsic endothelial differentiation potential. Once iso-
lated, ADSC, BMSC, and DPSC showed multilineage differentiation 
capability and high expression of the main undifferentiation markers 
that are associated with multipotentiality, such as CD73, CD90, and 
CD105.32
Interestingly, ndBMSC and ndDPSC showed some native ex-
pression of vWF and VEGF, which were present in HUVEC, although 
differentiation induction was able to increase this expression not 
only in these cell types, but also in ndADSC, and induced CD31 ex-
pression. These results confirm the endothelial differentiation po-
tential of these MSCs types, as previously demonstrated by several 
authors.36,31,37
Although the genetic and molecular signals associated with en-
dothelial differentiation of these cells need further characterization 
in future studies, we were able to demonstrate that a number of 
key proteins involved in angiogenesis and vasculogenesis became 
upregulated in differentiated MSCs using a protein array. According 
to these results, DPSC could have the highest in vitro endothelial 
differentiation potential, as dDPSC overexpressed 10 pro- angiogenic 
factors, with the highest expression corresponding to Amphiregulin 
and VEGF. Previous reports demonstrated that the elevated expres-
sion of Amphiregulin may act as an inductor of VEGF.38 The concom-
itant expression of the anti- angiogenesis factor PF4 may suggest 
that the in vitro endothelial differentiation process could be upregu-
lated by an intricate network often overlapping signaling pathways 
involving pro- and anti- angiogenic proteins39, in which PF4 could act 
as a regulator of the vascularization process.40
After in vitro characterization, we determined the vasculariza-
tion potential of each cell type in a three- dimensional model of bio-
artificial oral mucosa stroma grafted in vivo on athymic mice. This 
model was previously used by our group for the in vivo evaluation 
of different models of human oral mucosa due to the incapability 
of nude mice to reject human xenografts.22,41,16 Results confirmed 
that HOM was fully biocompatible in vivo, and animals grafted with 
the different types of HOM were free from any significant com-
plications or side effects. Since HOM grafted in vivo was analyzed 
at very early follow- up times (7 days), histological analysis showed 
three well- differentiated zones, with the most external zone A cor-
responding to rests of the grafted biomaterial, zone B corresponding 
to a cell- rich area in which the grafted HOM is actively remodeled 
and zone C corresponding to an interphase between the host niche 
containing blood vessels and the grafted bioartificial tissue, and our 
analyses demonstrated that part of the newly formed vessels con-
tained grafted human cells.
Most likely, these three areas can only be found at very early 
stages of in vivo follow- up, since previous works carried out by our 
research group showed that human oral mucosa substitutes grafted 
in nude mice for longer periods of time became fully integrated, and 
F I G U R E  1 0  Quantification of the number of cells and blood vessels showing positive signal for each endothelial cell marker (VEGF, CD31, 
vWF, and CD34) on each type of sample grafted in vivo in laboratory animals. In zone B, the number of positive cells per mm2 is shown, 
whereas the microvessel density (MVD) corresponding to the number of positive vessels found per mm2 is shown for zone C. HOM- HUVEC: 
artificial oral mucosa stroma containing HUVEC; HOM- HFOM: artificial oral mucosa stroma containing only oral mucosa fibroblasts; 
HOM- ndADSC, HOM- ndBMSC, and HOM- ndDPSC: artificial oral mucosa stroma containing each type of non- differentiated MSC; HOM- 
dADSC, HOM- dBMSC, and HOM- dDPSC: artificial oral mucosa stroma containing differentiated MSCs. Significant values of the comparison 
between all study groups vs HOM- HUVEC control cells were indicated with superscript a. Significant values of the comparison between all 
study groups vs HOM- HFOM negative control group were indicated with superscript b
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these three zones could not be identified.42 The fact that zone A 
contained very few cells could be explained by the direct contact 
with air, which could induce cells to migrate to deeper zones, as pre-
viously demonstrated.43
To determine the capability of each type of HOM to induce blood 
vessels formation, we performed a microvessel density (MVD) analysis 
in zone C of each type of HOM grafted in vivo, since this area corre-
sponded to the limit between the host tissue and the grafted HOM. 
Along with the analysis of MVD, we used a combination of four dif-
ferent endothelial cell markers to assess the presence of blood vessels 
at each sample type.23 The reason for this is that endothelial cells are 
highly heterogeneous, and there is a lack of a fully sensitive and spe-
cific trouble- free endothelial marker.23,44 Although all these markers 
are able to identify blood vessels, it has been demonstrated that the 
strongest expression of CD34 is found in small capillaries and acts as 
a marker of endothelial progenitor cells committed to develop small 
blood vessels45, whereas vWF is positive in higher- caliber vessels, 
being negative or weakly positive in capillaries.45 CD31 (PECAM- 1) is 
a transmembrane glycoprotein, member of immunoglobulin superfam-
ily, expressed on early and mature vascular endothelial cells, and can 
therefore be used to identify all types of blood vessels, although this 
marker has been especially characterized in veins.46,24 Finally, VEGF 
is considered to function as a panendothelial cell marker, although it 
is preferentially expressed upon arterial differentiation in association 
with the Notch signaling pathway.47 VEGF also has a direct effect on 
endothelial proliferation and migration48, and its overexpression is as-
sociated with endothelial differentiation.49 By using a combinatorial 
analysis with these four endothelial markers, we were able to evaluate 
the number of vessels being formed at zone C, and to contribute to 
characterize the type of vessels that develop in each sample type.
Results of these analyses showed that the use of HUVEC signifi-
cantly increased MVD at zone C, confirming previous reports demon-
strating the vascularization potential of these cells.25 Although further 
specific studies should be carried out in this sense, our results suggest 
that most blood vessels found at zone C corresponded to CD34- 
positive capillaries, with a lower number of vessels being positive for 
vWF, CD31, and VEGF. These results are plausible, since it is expected 
that low- size vessels are formed in the first place, followed by arteries 
and veins. Strikingly, we found that the use of MSC in HOM was able 
to increase MVD as compared to control HOM- HFOM, especially for 
HOM- dBMSC and HOM- dDPSC, which showed a very similar num-
ber of blood vessels that HOM- HUVEC. As in the previous case, most 
vessels were CD34- positive, again suggesting that the grafted tissue 
is initially occupied by a network of capillaries, and arteries and veins 
were less abundant at this stage of analysis. Future studies should be 
carried out at longer follow- up periods to determine the formation of 
larger size vessels. An interesting finding of the present work is that 
non- differentiated MSC also showed certain capability to induce blood 
vessel formation, although at a lower level than differentiated cells. 
These results are in agreement with our in vitro analyses showing that 
non- differentiated MSCs do express some endothelial cell markers 
in culture, which is in accordance with the pluripotential capability of 
these cells.50,51
After analyzing the vascular interphase of tissues grafted at zone 
C, we studied the area found at zone B corresponding to a region of in 
vivo remodeling of the implanted HOM. First, we found that no blood 
vessels were identified in this area, which is not surprising given the 
short follow- up time used for this analysis (one week). In this regard, 
we previously described that human bioartificial oral mucosa grafted 
in nude mice is able to develop abundant blood vessels after 4 weeks 
of in vivo implantation.42 Then, our analyses reveal that cells found at 
this zone are able to express relevant endothelial markers, suggesting 
that these cells could be in an early phase of differentiation to the en-
dothelial cell lineage. As expected, cells found in HOM- HFOM samples 
were virtually negative for all analyzed markers, whereas cells corre-
sponding to HOM- HUVEC samples expressed high amounts of VEGF, 
CD31, vWF, and CD34, which is in agreement with the endothelial dif-
ferentiation phenotype of HUVEC cells. As described for the blood ves-
sels found at zone C, we found that HOM- dBMSC and HOM- dDPSC 
showed very high amounts of cells with positive signal for these four 
markers, with no differences with control HOM- HUVEC samples, while 
HOM- dADSC and HOM containing non- differentiated MSC showed 
a trend to improve the results found with control HOM- HFOM, but 
were only comparable or even higher than HOM- HUVEC for HOM- 
dADSC analyzed with VEGF and for HOM- ndBMSC, HOM- ndDPSC, 
and HOM- dADSC with CD34. Again, these results may imply that the 
use of specific cell types in HOM could be associated with an active 
process of cell differentiation toward the endothelial cell lineage, which 
could generate mature blood vessels in a more advanced stage of dif-
ferentiation at increased follow- up times. We may also hypothesize 
that differentiating cells could be migrating to zone C to contribute to 
blood vessel formation in this area. Future works should confirm or dis-
miss these hypotheses.
The fact that cell density was very high at zone B could also favor 
endothelial differentiation. In this regard, it has been demonstrated 
that endothelial cells undergoing vascular differentiation tend to mi-
grate and form dense cell clusters, since a close cell- cell interaction is 
necessary to form well- established vascular networks.52,53
An unsolved question is the mechanism by which cells are able 
to increase MVD in HOM. One possibility is that most blood vessels 
found at zone C are formed by angiogenesis by cell sprouting from 
host vessels, whereas cells undergoing endothelial differentiation at 
zone B could correspond to HOM cells that will migrate and join the 
vascular network at zone C. However, it is also possible that the in-
creased number of vessels found at zone C of certain groups of sam-
ples (especially, HOM- dBMSC and HOM- dDPSC) is a consequence of 
a vasculogenesis process in which grafted cells form de novo vascular 
networks that interconnect and integrate with the host vessels. Most 
likely, a combined mechanism including an active process of angiogen-
esis and vasculogenesis may occur in these cases. This hypothesis is in 
agreement with the results found for the immune detection of human 
cells demonstrating that vessels consisting of human cells along with 
vessels composed by non- human cells were present at the graft site. 
Previous studies demonstrated that the anti- human mitochondria an-
tigen antibody used here is specific for human cells and allows the 
identification of human cells grafted in mice.54,55
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The present study has several limitations. In the first place, in 
vitro angiogenesis assays, such as tube formation experiments, 
should be performed to demonstrate the in vitro angiogenesis poten-
tial of each type of MSC. In the second place, future studies should 
determine with higher accuracy the origin of the vessels found at the 
implanting area and the exact percentage of vessels derived from 
the grafted tissue and from host vessels.
In summary, our results suggest that the use of certain types of 
MSC in HOM, especially HOM- dBMSC and HOM- dDPSC, is associ-
ated with a significant increase in the formation of blood vessels once 
grafted in vivo. These results open the door to the future use of pre- 
differentiated MSC to induce the rapid formation of a vascular net-
work after oral mucosa implantation in patients, especially in cases 
when the implantation site is affected by associated conditions alter-
ing tissue grafting. In addition, future studies should be carried out to 
determine whether the results obtained for the human oral mucosa 
are also applicable to the generation of other types of human tissues 
and organs by tissue engineering with increased vascularization po-
tential, such as the human skin and palate.
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